Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile Marcos Cruces Olivar, Allan D. Burboa, Yolanda M. Gómez

Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis Jesús Tornero-Molina, Mercedes Alperi-López, Ivan Castellví, Juan José de Agustín-de Oro, Alejandro Escudero, Rosario García-Vicuña, Miguel Ángel González-Gay, Cristina Hidalgo, Esteban Rubio, Raimon Sanmartí, Núria Casamira, Jaime Calvo-Alén

Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price Mariángeles González Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, Francisco Moreno, Chamaida Plasencia, Francisco Gayá, Alicia Herrero, Alejandro Balsa